Table TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2009 or most recent year available [see all tables in this series...]

Part (iii) New clients by country and rates of injection of primary drug (%)

Country		Year	Opioids % Injecting	Cocaine % Injecting	Amphetamines% injecting	Total % Injecting
Belgium		2009	17.3	3.1	11.4	4.7
Bulgaria		2009	77.5	:	7.7	72.9
Czech Republic		2009	80.4	8.7	72.7	58.3
Denmark		2009	8.3	2.9	1.5	1.5
Germany	(1)	2009	33.7	7.2	0.8	10.7
Estonia		2009	89.2	:	70.0	84.1
Ireland		2009	23.0	0.2	0.0	10.2
Greece	(2)	2009	38.7	7.7	0.0	31.2
Spain	(3)	2008	12.0	1.0	0.4	2.7
France		2009	12.4	4.9	0.0	3.4
Italy		2009	45.0	5.7	16.1	21.2
Cyprus		2009	60.5	0.0	0.0	23.5
Latvia		2009	98.7	50.0	59.3	53.2
Lithuania	(4)	2009	98.8	:	13.3	85.2
Luxembourg	(5)	2009	:	:	:	:
Hungary		2009	65.1	0.0	17.5	3.7
Malta		2009	53.5	7.9	:	28.9
Netherlands		2009	11.9	0.1	0.9	0.9
Austria		2009	29.6	0.9	0.0	14.7
Poland	(3)	2008	40.5	0.0	2.3	6.2
Portugal	(6)	2009	:	:	:	12.5
Romania		2009	91.6	7.7	0.0	64.6
Slovenia		2009	39.3	22.2	0.0	32.8
Slovakia		2009	79.8	0.0	32.1	34.7
Finland		2009	76.6	:	66.0	40.9
Sweden		2009	19.0	0.0	42.7	11.2
United Kingdom		2009	30.4	0.9	18.3	13.6
Croatia		2009	56.8	0.0	0.0	25.5
Turkey		2009	41.9	0.0	:	21.1
Norway		:	:	:	:	:
Total			35.3	2.7	26.7	13.9

Notes:

 : Indicates no data available             

 Drug specific percentages are of clients whose primary drug and usual route of administration is known. Total injecting considers all the injection cases regardless of the primary drug being known or not. 

 Injecting as a route of administration is not reported for ecstasy, cannabis and other drugs. 

 (1) Amphetamines refer to stimulants in general. Data on route of administration refer to primary and non primary drugs. 

 (2) 'Speedball' is included in the category 'Other substances'. 

 (3) Last data available refer to 2008. 

 (4) Amphetamines refer to stimulants in general. 

 (5) Data on first treatments (breakdown by drug and route of administration) were not reported for 2009 as the figures were too small. 

 (6) Data do not account for drug breakdown. 

 See also ‘General notes for interpreting data’ on the Explanatory notes and help page. 

Sources:

 Reitox national reports 2010 — TDI tables V. 1.0-2010. See Table TDI-0 for details on sources. 

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)